Bioavailability of Dolutegravir 10 mg and 5 mg Tablets

Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (8 arms), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time of Dose Extrapolated to Infinite Time at 72 hours, Area Under the Plasma Concentration-time Curve From Time of Dose to Last Measurable Concentration at 72 hours and 1 more. Started May 2017; status: completed.